What is HC Wainwright’s Estimate for RARE FY2024 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Ultragenyx Pharmaceutical in a research note issued on Wednesday, November 6th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings of ($6.26) per share for the year, up from their previous forecast of ($6.34). HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($1.37) EPS, Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.29) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at $3.46 EPS and FY2028 earnings at $9.33 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The company had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same period last year, the business posted ($2.23) EPS. The company’s revenue was up 42.3% on a year-over-year basis.

RARE has been the topic of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Barclays decreased their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $86.69.

Ultragenyx Pharmaceutical Trading Down 0.2 %

Shares of RARE stock opened at $50.43 on Friday. The business’s 50 day moving average is $55.19 and its two-hundred day moving average is $48.12. Ultragenyx Pharmaceutical has a twelve month low of $34.06 and a twelve month high of $60.37. The company has a market capitalization of $4.65 billion, a P/E ratio of -6.91 and a beta of 0.58.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the first quarter valued at about $28,000. nVerses Capital LLC purchased a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth about $33,000. UMB Bank n.a. boosted its position in shares of Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth about $56,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth about $107,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,556 shares of company stock valued at $1,515,967 over the last three months. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.